TY - JOUR
T1 - The SOX2 status of disseminated tumor cells in breast cancer patients treated with neoadjuvant chemotherapy
AU - Krawczyk, Natalia
AU - Janowski, Kathrin
AU - Banys-Paluchowski, Maggie
AU - Staebler, Annette
AU - Neubauer, Hans
AU - Meisner, Christoph
AU - Hartkopf, Andreas
AU - Brucker, Sara
AU - Wallwiener, Diethelm
AU - Fehm, Tanja
N1 - Publisher Copyright:
© 2021 International Institute of Anticancer Research. All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Background/Aim: Detection of disseminated tumor cells (DTCs) after systemic treatment predicts poor prognosis in breast cancer patients. The aim of our study was to assess the expression of stem-cell marker SOX2 on DTCs and in the primary tumor of patients treated with neoadjuvant chemotherapy (NAT). Materials and Methods: In 170 DTCpositive patients after NAT an additional slide of bone marrow aspirate was stained by double immunofluorescence to detect SOX2-positive DTCs. The SOX2 status of the primary tumor was assessed using the same antibody. Results: The SOX2-status of DTCs was determined in 62 patients and 20 of those (32%) had SOX2 positive DTCs. The SOX2 status of DTCs was not associated with any of the clinicopathological factors. A total of 36% of the patients with a SOX2-negative tumor showed SOX2-positive persistent DTCs. Conclusion: SOX2-positive DTCs can be detected in breast cancer patients after NAT, even in patients with SOX2-negative primary tumors. This suggests that these populations may have evolved independently of each other.
AB - Background/Aim: Detection of disseminated tumor cells (DTCs) after systemic treatment predicts poor prognosis in breast cancer patients. The aim of our study was to assess the expression of stem-cell marker SOX2 on DTCs and in the primary tumor of patients treated with neoadjuvant chemotherapy (NAT). Materials and Methods: In 170 DTCpositive patients after NAT an additional slide of bone marrow aspirate was stained by double immunofluorescence to detect SOX2-positive DTCs. The SOX2 status of the primary tumor was assessed using the same antibody. Results: The SOX2-status of DTCs was determined in 62 patients and 20 of those (32%) had SOX2 positive DTCs. The SOX2 status of DTCs was not associated with any of the clinicopathological factors. A total of 36% of the patients with a SOX2-negative tumor showed SOX2-positive persistent DTCs. Conclusion: SOX2-positive DTCs can be detected in breast cancer patients after NAT, even in patients with SOX2-negative primary tumors. This suggests that these populations may have evolved independently of each other.
UR - http://www.scopus.com/inward/record.url?scp=85107545288&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/ed956e74-24ff-3133-b761-06c0cd99856c/
U2 - 10.21873/anticanres.15066
DO - 10.21873/anticanres.15066
M3 - Journal articles
C2 - 34083275
AN - SCOPUS:85107545288
SN - 0250-7005
VL - 41
SP - 2849
EP - 2858
JO - Anticancer Research
JF - Anticancer Research
IS - 6
ER -
